Introduction and Objective: HZ has been associated with a higher risk of cardiovascular events, but evidence in T2DM is limited. This analysis assessed associations between HZ and MI/IS in older adults with T2DM.Methods: Using US administrative claims and EHR data (Optum Market Clarity, 2016-2024), adults with T2DM and HZ were identified by ICD-10 diagnosis codes. […]
Read MoreMonth: June 2026
Factors associated with hypoglycemic or hyperglycemic events during Ramadan among persons with diabetes in Qatar
Background Despite the high prevalence of diabetes in Qatar, Ramadan-related glycemic events remain inadequately characterized. This study examined sociodemographic, clinical and behavioral factors independently associated with hypoglycemic or hyperglycemic events among patients with diabetes during Ramadan in Qatar. Methods A retrospective analysis was conducted using routinely collected data from the Qatar Diabetes Association (QDA) Ramadan […]
Read More1318-OR: CNTY-813: Scalable Production of Allo-Evasion 5.0-Engineered IPSC Beta Islets for Off-the-Shelf Cell Therapies
Introduction and Objective: Type 1 diabetes cell therapies aim to restore normoglycemia by replacing lost beta cells, but low clinical supply and the need for chronic immune suppression are key challenges. CNTY-813 overcomes these challenges via clinical-scale production of Allo-Evasion™ 5.0-engineered iPSC-derived beta islets that are engineered for immune evasion. Thus, CNTY-813 provides an off-the-shelf, […]
Read More1343-OR: Continuous Glucose Monitoring vs. Blood Glucose Monitoring in Patients with Type 2 Diabetes Managed on Insulin in Primary Care: The GluCoCare Study
Introduction and Objective: We evaluated the effectiveness of CGM versus BGM in the pragmatic management of T2D on insulin in primary care, in a large randomized controlled trial in the upper Midwest.Methods: This two-arm trial was cluster-randomized based on primary care clinic attendance: (BGM 25 clinics) or CGM (25 clinics). We recruited 360 adults with […]
Read More1298-OR: CGM-Derived Disposition Index in Stage 1 Type 1 Diabetes (T1D)
Introduction and Objective: Monitoring of beta cell function in those with preclinical T1D relies on serial frequently sampled oral glucose tolerance tests (OGTT), which poses major challenges given the practical burden and expense of this test. Herein, we validated a fully CGM-derived disposition index (DICGM) – a proxy of beta cell function -computed against the […]
Read More1342-OR: CGM Data Provides Weekly Insulin Efsitora Dose Guidance Equivalent to the Current Standard of FBG and Hypoglycemia Events for T2D Insulin Naïve Adults: A Retrospective Analysis
Introduction and Objective: Basal insulin dose titration is traditionally guided by self-monitored FBG and documented hypoglycemic events. This retrospective analysis evaluated CGM-derived indicators for use in dose titration of weekly basal insulin in insulin-naïve adults with T2D.Methods: CGM indicators of FBG were calculated from 3730 weekly insulin dose decisions, while hypoglycemic events were assessed using […]
Read More1284-OR: Preliminary Evidence for a Training Program Designed to Improve the Digital Health Literacy of Adults with Diabetes
Introduction and Objective: Despite the widespread digitalization of diabetes care, significant disparities remain in individuals’ skills and confidence using digital health tools. We consulted with patients and clinicians to develop a program, called ADDS (Assistance with Diabetes Digital health Skills), to improve the digital health literacy of adults with type 2 diabetes (T2D) and explored […]
Read More1328-OR: Short-Term Glucagon Adaptation to an Isocaloric Ketogenic Diet in Obese Individuals with Type 2 Diabetes
Introduction and Objective: We previously (BMJ Open Diab: e004199, 2024) showed that a 10-day weight-maintaining ketogenic diet in individuals with type 2 diabetes did not change OGTT responses or insulin sensitivity (two-step euglycemic clamp) but increased insulin secretion.To examine the effect of the 10-day weight-maintaining ketogenic or standard diet on fasting plasma glucagon and OGTT […]
Read More1278-OR: IGFBP7 Blockade Protects from Diabetic Cardiomyopathy
Introduction and Objective: Despite being a major contributor to reduced life expectancy in type 1 diabetes (T1D), cardiovascular disease (CVD) and T1D-associated cardiomyopathy remain poorly understood. Insulin-like growth factor binding protein-7 (IGFBP7), a member of the IGFBPs, was found elevated in serum of patients with heart failure and kidney disease. Clinical studies in patients with […]
Read More1327-OR: The Contribution of Circulating Amino Acid, Glucose and Insulin Concentrations to Glucagon Secretion
Introduction and Objective: Obesity and prediabetes are characterized by abnormal glucagon response to glucose and amino acids (AA). Elevated AA concentrations, seen in these states, are associated with increased risk of type 2 diabetes. The relative contributions of AA, glucose and insulin to glucagon secretion is unknown.Methods: Lean (BMI: 23 ± 0.5 kg/m2, n = […]
Read More